Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
ZYKADIA (CERITINIB) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
ZYKADIA
NDA
Get alerts
CERITINIB | N211225 | NOVARTIS PHARMACEUTICALS CORP
1 strength
8 unique patents
0 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
DMF
Approvals
Label
Products
Patent Timeline
8 unique patents by expiration date
Expired (1)
Active (7)
Today
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
Today
7893074
Apr. 25, 2026
7964592
Apr. 29, 2028
8039479
Jun. 29, 2030
8377921
Nov. 20, 2027
8399450
Nov. 20, 2027
8703787
Feb. 2, 2032
9309229
Jan. 18, 2032
12357630
Dec. 13, 2037
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — 150MG
RLD
8 patents
0 exclusivities
▴
TABLET;ORAL | Approved: Mar 18, 2019
Patents (8)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
7893074
Apr 25, 2026
—
Yes
Yes
—
—
7964592
Apr 29, 2028
—
Yes
Yes
—
—
8039479
Jun 29, 2030
—
Yes
Yes
—
—
8377921
Nov 20, 2027
—
—
—
U-1179
TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)
—
8399450
Nov 20, 2027
—
Yes
Yes
—
—
8703787
Feb 2, 2032
—
—
—
U-1179
TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)
—
9309229
Jan 18, 2032
—
Yes
Yes
—
—
12357630
Dec 13, 2037
—
—
—
U-3096
TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST
—